Skip to content
← All questions
AI-generated draftEvidence through 2026-09-20Uncertainty: moderateRe-checked automatically every month, last checked Mon 19 Oct
medical informationThis information is for general educational purposes and is not professional advice; consult a qualified clinician for medical decisions.

Answer

Recent approaches emphasize earlier, biomarker-confirmed treatment with anti-amyloid monoclonal antibodies (lecanemab and donanemab), while tau-targeting therapies, antisense oligonucleotides, GLP-1 receptor agonists, and other disease-modifying strategies are among the most actively studied next-generation approaches.

Current evidence

Two anti-amyloid monoclonal antibodies have received regulatory approval in the United States: lecanemab and donanemab. In the phase 3 Clarity AD trial, lecanemab reduced cognitive decline by 27% over 18 months compared with placebo, but was associated with amyloid-related imaging abnormalities (ARIA). Donanemab similarly slowed decline in early symptomatic Alzheimer's disease in the TRAILBLAZER-ALZ 2 trial. These results have shifted practice toward treating patients with biomarker-confirmed early disease and monitoring for ARIA. Beyond amyloid, tau-targeting approaches are advancing: an antisense oligonucleotide targeting tau mRNA (BIIB080/MAPTRx) reduced tau protein in cerebrospinal fluid in a phase 1b trial. Active and passive tau immunotherapies are also in clinical development. GLP-1 receptor agonists, originally developed for diabetes and obesity, are being tested in Alzheimer's disease because of links between metabolic dysfunction and neurodegeneration. Blood-based biomarkers such as plasma p-tau217 are increasingly used to identify eligible patients and monitor treatment effects.

Limitations

Despite these advances, the clinical effects of approved anti-amyloid antibodies are modest, and ARIA, including brain edema and microhemorrhages, requires MRI monitoring and can be serious. Many tau and metabolic therapies remain experimental, with phase 2 or early-phase data only, and some trials have failed to meet primary endpoints. Blood biomarker tests are not yet universally standardized, and access to PET or CSF confirmation remains uneven.

What this means

These developments are likely to reinforce a precision-medicine model: patients with biomarker-confirmed Alzheimer's disease may be treated earlier, with careful risk stratification for ARIA. Future progress may depend on combination therapies that target both amyloid and tau, as well as on scalable blood-based biomarkers to make trials and clinical care more inclusive.

Evidence

Sources (9)

Last checked 2026-09-20Source details

Confidence is an AI estimate, not an independent assessment of source quality.

  1. Reputable websiteAI confidence: 95%
  2. FDA Approves Treatment for Adults with Alzheimer's Disease

    U.S. Food and Drug Administration · 2024-07-02

    Reputable websiteAI confidence: 90%
  3. Peer reviewedAI confidence: 85%
  4. Lecanemab in Early Alzheimer's Disease

    van Dyck CH, et al. · 2023-01-05

    Peer reviewedAI confidence: 98%
  5. Peer reviewedAI confidence: 95%
  6. Peer reviewedAI confidence: 90%
  7. Peer reviewedAI confidence: 85%
  8. Reputable websiteAI confidence: 80%
  9. GuidelineAI confidence: 90%
Living answer

Update history

  1. Initial answerVersion 1
    Initial generation summarizing recent Alzheimer's treatment approaches as of September 2026.9 sources · AI-generated

Sign in to join the discussion

No comments yet on this answer. Comments and your saved library are available to signed-in readers.